ArticlePharmacology, biochemistry, and behavior2020
In vitro and in vivo pharmacological evaluation of the synthetic cannabinoid receptor agonist EG-018.
Article in Pharmacology, biochemistry, and behavior, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 17 citations in OpenAlex.
- Structure-Activity Relationship and Functional Evaluation of Cannabinoid Type-1 Receptor.Biomolecules & therapeutics · 2024Article
- Evaluation of cannabimimetic effects of selected minor cannabinoids and Terpenoids in mice.Progress in neuro-psychopharmacology & biological psychiatry · 2024Article
- The synthetic cannabinoid 5-fluoro ABICA upregulates angiogenic markers and stimulates tube formation in human brain microvascular endothelial cells.Journal of Taibah University Medical Sciences · 2024Article
- Evaluating signaling bias for synthetic cannabinoid receptor agonists at the cannabinoid CBPharmacology research & perspectives · 2023Article
- "Spice"-related deaths in and around Munich, Germany: A retrospective look at the role of synthetic cannabinoid receptor agonists in our post-mortem cases over a seven-year period (2014-2020).International journal of legal medicine · 2023Article
- In vitro and in vivo pharmacology of nine novel synthetic cannabinoid receptor agonists.Pharmacology, biochemistry, and behavior · 2022Article
- Structure-activity relationships of valine,RSC medicinal chemistry · 2022Article
- Exploring determinants of agonist efficacy at the CB1 cannabinoid receptor: Analogues of the synthetic cannabinoid receptor agonist EG-018.Pharmacology research & perspectives · 2022Article
- Synthesis and pharmacological evaluation of newly detected synthetic cannabinoid receptor agonists AB-4CN-BUTICA, MMB-4CN-BUTINACA, MDMB-4F-BUTICA, MDMB-4F-BUTINACA and their analogs.Frontiers in psychiatry · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 3 countries.
Funding
Abstract
Synthetic cannabinoid receptor agonists (SCRAs) possess high abuse liability and complex toxicological profiles, making them serious threats to public health. EG-018 is a SCRA that has been detected in both illicit products and human samples, but it has received little attention to date. The current studies investigated EG-018 at human CB
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.